[Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 162–73

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024; 12: 162–73—In table 3 of this Article, row 11 should have read “32 (10%)” for the survodutide total column. This correction has been made to the online version as of Dec 17, 2025.